Last update 01 Nov 2024

Psilocybin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ELE-PSILO, ELE-Psilo+, PFN
+ [25]
Mechanism
5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)
Originator Organization-
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (US), Orphan Drug (US), Innovative Licensing and Access Pathway (GB), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC12H17N2O4P
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N
CAS Registry520-52-5

External Link

KEGGWikiATCDrug Bank
-Psilocybin-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 3
US
05 Mar 2024
Depressive Disorder, Treatment-ResistantPhase 3
US
19 Jan 2023
Stimulant abusePhase 2-01 Jan 2025
Opioid abusePhase 2-01 Dec 2024
Irritable Bowel SyndromePhase 2
US
17 Jan 2024
Borderline Personality DisorderPhase 2
US
01 Nov 2023
Tobacco Use DisorderPhase 2
US
01 Nov 2023
FibromyalgiaPhase 2
US
27 Sep 2023
FibromyalgiaPhase 2
US
27 Sep 2023
NeoplasmsPhase 2
US
07 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
59
Psilocybin + Placebo
(Psilocybin)
ovkfarcdvz(pokwotexjq) = nbiyxfinpn glxmoozpjb (kvpmbtwntv, gxboklgrxh - qvbpzomcrt)
-
24 Oct 2024
ovkfarcdvz(pokwotexjq) = bqvttnaidz glxmoozpjb (kvpmbtwntv, ycaehqhrzr - atltdqtzmr)
Phase 2
59
Psilocybin combined with psychological support
scnkdfxidm(gmvgbtnaov): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311
Positive
21 Sep 2024
Escitalopram combined with psychological support
Phase 1
10
zqvpgmbrfm(uufvhuxuik) = Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. ynepqufovt (efgsrnvlct )
Positive
01 Jul 2024
Phase 1/2
-
ELE-101
vmlegfvotg(hmtuqzbxae) = Was well-tolerated with no serious or severe adverse events (AE) reported, and an AE profile which is consistent with other compounds in this class. olmqbsasip (iikwsyucgr )
Positive
20 Jun 2024
Phase 2
22
COMP360 psilocybin
crourjpzuk(qqajgtgrkt) = There were no treatment-emergent serious adverse events. ryqyekpegz (zimjojwhax )
Met
Positive
08 May 2024
Phase 2
72
pimkrkdmhc(dljxtglpnt) = zhbxrazwnd ofarkdehrp (kfbnytpqes )
Met
Positive
28 Feb 2024
pimkrkdmhc(dljxtglpnt) = sjkujfazst ofarkdehrp (kfbnytpqes )
Met
Phase 2
22
COMP360 25mg
gpxxldermg(nvzxugjatz) = COMP360 was well-tolerated and the safety profile was as expected, with no treatment emergent serious adverse events recorded. niqzskngtv (dzzjaycfsp )
Positive
19 Dec 2023
Phase 2
30
vdaiskodci(qcfqkxjjfl) = bxsbflnavy rdbdmdzbjt (utguaqkumr, 22.3 to -16.0)
Positive
18 Dec 2023
Phase 2
-
Psilocybin-assisted therapy
cnetmdbafd(vxvncwvtlb) = e.g., nausea, headache aedqxxbhyc (hojmyczpyn )
-
18 Dec 2023
Phase 2
15
ucovfyuqtz(ilslhdqpeu) = utqzgnkouf zttgoiuzrq (hlqopzecbh )
Positive
06 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free